India's Shilpa Medicare can make 100-200 million doses of Covid-19 shot


 

Indian drug maker Shilpa Medicare Ltd has the production capacity to make 100-200 million doses of a recombinant vaccine for COVID-19, a company executive told Reuters on Wednesday.

The company's shares jumped as much as 9.2% on India's National Stock Exchange following the news. Read More

Comments

Popular posts from this blog

Instagram adds group video call, new camera effects to app: How they work

3 Investment Strategies for Financial Independence!

G7 pledges 870 mn Covid vaccine doses, half to be delivered by 2021-end